Charles Erlichman, Daniel J Sargent. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, HumanizedAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCamptothecin/administration & dosageCamptothecin/adverse effectsCamptothecin/analogs & derivativesCetuximabColorectal Neoplasms/drug therapyErbB Receptors/antagonists & inhibitorsErbB Receptors/metabolismExanthema/chemically inducedHumansIrinotecanResearch DesignTopoisomerase I Inhibitors
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsTopoisomerase I InhibitorsIrinotecanErbB ReceptorsCetuximabCamptothecin
Year: 2004 PMID: 15269321 DOI: 10.1056/NEJMe048151
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245